Skip to main content
All lobbying filings

EMPIRE CONSULTING GROUP

EMPIRE CONSULTING GROUP filed a Q3 report for VERTEX PHARMACEUTICALS INCORPORATED on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED · Biotechnology company

All filings by EMPIRE CONSULTING GROUP · Everything VERTEX PHARMACEUTICALS INCORPORATED has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • MICHAEL HAYES New on this filing
    Previously held: Deputy Director, Office of Public Engagement, The White House; Director, National Security Council, The White House; U.S. Diplomat, Department of State; Legislative Fellow, U.S. House of Representatives

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Health Issues

Issues related to Kidney health, HR 1227 Alternatives to Pain Act.

 Bills named in this filing 1

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem